Key points are not available for this paper at this time.
Richard McManus, Mark Caulfield, Bryan Williams respond to criticisms of the 2011 NICE guideline, arguing that it reflects the reduced costs of generic drugs and new evidence on cardiovascular risk reduction
McManus et al. (Fri,) studied this question.